Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 May;6(10):194.
doi: 10.21037/atm.2018.03.29.

The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials

S John Weisnagel  1
Affiliations
Editorial

The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials

S John Weisnagel. Ann Transl Med. 2018 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author was a clinical trial investigator in several of the above mentioned studies. In particular, he participated in or is still involved in the following: TECOS (sitagliptin by Merck), LEADER (liraglutide by Novo-Nordisk), REWIND (dulaglutide by Eli Lilly), DECLARE (dapagliflozin by Astra Zeneca).

Comment on

  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
    Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Holman RR, et al. N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14. N Engl J Med. 2017. PMID: 28910237 Free PMC article. Clinical Trial.

References

    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. 10.1056/NEJMoa072761 - DOI - PubMed
    1. FDA. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: US Department of Health and Human Resources, 2008.
    1. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab 2018;20 Suppl 1:5-21. 10.1111/dom.13129 - DOI - PubMed
    1. Steen O, Goldenberg RM. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. Can J Diabetes 2017;41:517-23. 10.1016/j.jcjd.2017.08.241 - DOI - PubMed
    1. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. 10.1056/NEJMoa1307684 - DOI - PubMed

LinkOut - more resources